Elliott Management has built a large stake in GlaxoSmithKline

I have been buying GlaxoSmithKline stock ahead of the proposed split. An activist hedge fund taking a large stake in the company suggests they want something different. Here is what I am doing now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

According to the Financial Times, activist hedge fund Elliott Management has built a multibillion-pound stake in GlaxoSmithKline (LSE:GSK). The news broke today, and the GlaxoSmithKline share price is up 4.3% at the time of writing. Given that the broader FTSE 100 is up only 0.58%, and other large-cap pharma stock prices have budged only slightly, it’s reasonable to assume that Glaxo shareholders have taken the news well.

Activist hedge fund target

Elliott Management — which is headed up by billionaire investor Paul Singer — has a history of taking large stakes in companies that it feels are underperforming. It then uses its influence as a large shareholder to push the board to make changes that it thinks will increase shareholder value.

The GlaxoSmithKline share price has been underperforming its peers. It is down a little under 20% over three years. In contrast, the share prices of AstraZeneca and Pfizer, two notable peers, are up around 60% and 20%, respectively. Therefore, GlaxoSmithKline becoming the target of an activist hedge fund like Elliott Management is not a big surprise.

What is surprising is that major changes are already underway at GlaxoSmithKline. Investors have argued for years that the GlaxoSmithKline share price would do better if the company were to split. Investors calling for such a change are getting what they wanted.

What is Elliott Management after?

GlaxoSmithKline is due to split in 2022. The cash cow consumer healthcare business will go it alone with higher leverage and probably pay a stable dividend. The riskier biopharma business, dubbed ‘New Glaxo’, should emerge with lower debt and be able to invest heavily in a pipeline of new drugs.

GlaxoSmithKline told its shareholders about this plan over a year ago. Today’s announcement that Elliott Management has built a large stake suggests it is unhappy with the plan in part or in full. There is concern that the current CEO of GlaxoSmithKline, who previously has a successful tenure at personal care company L’Oréal, plans to head up the biopharma business after the split. The consumer healthcare division is thought to be better suited to the current CEO’s skill set.

It’s worth noting that GlaxoSmithKline has issued a dividend warning. After the split, the aggregate dividend is likely to be lower than the 80p paid for 2019. Perhaps this could be reason enough for Elliott to lobby against the company considering a lower payout.

It has also been suggested that GlaxoSmithKline’s sluggishness in developing a coronavirus vaccine, given its vaccine business is the jewel in its crown, is a motivating factor apart from the split. It’s worth noting that GlaxoSmithKline is collaborating on at least two Covid-19 vaccines at present.

GlaxoSmithKline share price

Without knowing what Elliott management wants, it’s impossible to speculate on the long-term effects of the activist hedge fund’s involvement on the GlaxoSmithKline share price. I am in favour of the split. Naturally, I would rather Elliott did not derail it. But, I can see the merits of arguing for the CEO to move to control the consumer healthcare business. As for vaccines, playing the long game might have been a shrewd move. Rolling vaccines out in record time have caused difficulties for others. It looks like Covid-19 will require multiple vaccines for quite some time.

Until I know more, I am continuing to buy GlaxoSmithKline shares ahead of the anticipated split.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

Here’s how long it’s taken £1k of Nvidia stock to turn into £10k today!

Our writer explains how money invested in Nvidia stock less than three years ago has grown in value over tenfold…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
US Stock

3 red flags I’m seeing right now for the S&P 500

Jon Smith points out some concerns he has with the S&P 500 at current levels and picks one stock he's…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

UK dividend shares are outperforming US tech stocks!

UK dividend shares aren’t just for passive income investors. Over the last 12 months, they’ve been outperforming their US tech…

Read more »

DIVIDEND YIELD text written on a notebook with chart
US Stock

Here’s how much passive income an investor could make with £2k in Meta stock

Jon Smith looks at Meta stock from a different angle to normal, considering it as an option for an investor's…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

1 of my top UK shares is up 15% in a day! Is it still a buy for me?

Celebrus shares are soaring after strong full-year results. At a P/E ratio below 13, is it one of the best…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

£10,000 invested in Jet2 shares 2 years ago is now worth…

Jet2 shares have surged in recent months and finally appear to be pushing towards fair value. Dr James Fox shares…

Read more »

piggy bank, searching with binoculars
Investing Articles

This FTSE 100 blue-chip could rise 26% in 12 months, according to brokers

While this FTSE 100 dividend stock has put investors through the wringer in recent years, some analysts see brighter skies…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

A 3-step passive income strategy to target major wealth

Want to invest in the stock market to build up a passive income stream? There's no fiendlishly complex multi-step mystique…

Read more »